N A Hanania

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial
    Nicola A Hanania
    Section of Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX 77030, USA
    Chest 142:119-27. 2012
  2. ncbi Influenza vaccine in patients with asthma
    Nicola A Hanania
    Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Vaccines 5:111-8. 2006
  3. ncbi Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial
    Nicola A Hanania
    Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 69:1205-16. 2009
  4. ncbi Revisiting asthma control: how should it best be defined?
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 20:483-92. 2007
  5. ncbi Accidental hypothermia
    N A Hanania
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Crit Care Clin 15:235-49. 1999
  6. ncbi The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma
    Nicola A Hanania
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Respir Med 101:1007-14. 2007
  7. ncbi Targeting airway inflammation in asthma: current and future therapies
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, Houston, TX 77030, USA
    Chest 133:989-98. 2008
  8. ncbi The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 21:540-50. 2008
  9. ncbi Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 29:2121-33. 2007
  10. ncbi Treatments for COPD
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Respir Med 99:S28-40. 2005

Research Grants

  1. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2007

Detail Information

Publications48

  1. ncbi The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial
    Nicola A Hanania
    Section of Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX 77030, USA
    Chest 142:119-27. 2012
    ..This study assessed the dose response, efficacy, and safety of VI at doses of 3 to 50 μg in patients with moderate to severe COPD...
  2. ncbi Influenza vaccine in patients with asthma
    Nicola A Hanania
    Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Vaccines 5:111-8. 2006
    ..In this review, the risk-versus-benefit of influenza vaccination in children and adults with asthma is evaluated, based on the current evidence...
  3. ncbi Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial
    Nicola A Hanania
    Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 69:1205-16. 2009
    ..The addition of nebulized formoterol to tiotropium in maintenance treatment of COPD provided clinically meaningful, statistically significant and sustained improvements in pulmonary function without additional adverse effects...
  4. ncbi Revisiting asthma control: how should it best be defined?
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 20:483-92. 2007
    ..Alternate assessment measures are therefore often needed to assess asthma control and achieve a successful treatment outcome. This review will provide practical guidance relevant to the clinical assessment of asthma control...
  5. ncbi Accidental hypothermia
    N A Hanania
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Crit Care Clin 15:235-49. 1999
    ..Several rewarming techniques are available and the decision to use any of them depends on the degree of hypothermia, the condition of the patient, and the rewarming rate possible with the technique chosen...
  6. ncbi The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma
    Nicola A Hanania
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Respir Med 101:1007-14. 2007
    ..Current guidelines recommend repeated doses of albuterol for the emergency treatment of acute asthma. However, approximately one-third of patients show little or no initial response to this partial beta(2)-agonist...
  7. ncbi Targeting airway inflammation in asthma: current and future therapies
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, Houston, TX 77030, USA
    Chest 133:989-98. 2008
    ..This review provides an overview of the current and future approaches targeting airway inflammation in patients with asthma...
  8. ncbi The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 21:540-50. 2008
    ..Additional relevant references were identified from the reference lists of selected papers. Only studies that compared a combined LABA+ICS therapy with its monotherapy components were selected for inclusion in this manuscript...
  9. ncbi Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 29:2121-33. 2007
    ..Published practice guidelines and treatment algorithms for COPD are designed to increase awareness of the problem and improve patient care; however, <40% of subjects diagnosed with COPD are receiving appropriate maintenance therapy...
  10. ncbi Treatments for COPD
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Respir Med 99:S28-40. 2005
    ..The challenge will be to develop this base of knowledge in order to shape future research and allow clinicians to deliver tailored COPD management programmes for the growing number of patients afflicted with this disease...
  11. ncbi The safety and efficacy of arformoterol and formoterol in COPD
    Nicola A Hanania
    Baylor College of Medicine, Houston, Texas, USA
    COPD 7:17-31. 2010
    ..7 to -6.8). In this 6-month study, arformoterol and formoterol were well-tolerated, and their use was associated with improvement in pulmonary function and health status in subjects with COPD with no apparent development of tolerance...
  12. ncbi Beta-agonist intrinsic efficacy: measurement and clinical significance
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine and the Houston Veterans Administration Medical Center, Texas 77030, USA
    Am J Respir Crit Care Med 165:1353-8. 2002
  13. ncbi The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD
    Nicola A Hanania
    Baylor College of Medicine, Pulmonary Critical Care, Ben Taub General Hospital, 1504 Taub Loop, Houston, TX 77030, USA
    Chest 124:834-43. 2003
    ....
  14. ncbi Bronchodilator reversibility in COPD
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, Houston, TX 77030, USA
    Chest 140:1055-63. 2011
    ..This review outlines recent findings about the prevalence and usefulness of bronchodilator reversibility in patients with COPD based on the available literature and proposes areas of future research...
  15. ncbi Anti-inflammatory activities of beta2-agonists
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop Houston 77030, USA
    Curr Drug Targets Inflamm Allergy 3:271-7. 2004
    ..However, when given concomitantly with inhaled corticosteroids, beta2-agonists may potentiate the anti-inflammatory effect of corticosteroids, improve asthma control and prevent exacerbations...
  16. ncbi Safety of chronic obstructive pulmonary disease medications: a primary care perspective
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 123:72-9. 2011
    ..This article discusses the different medications available for COPD management and the factors affecting their safety based on current evidence...
  17. ncbi The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
    N A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 18:19-22. 2005
    ....
  18. ncbi Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
    Nicola A Hanania
    Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
    Respir Res 12:6. 2011
    ..Debate continues as to whether acute bronchodilator responsiveness (BDR) predicts long-term outcomes in COPD. Furthermore, there is no consensus on a threshold for BDR...
  19. ncbi Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ)
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Respir Med 104:1160-70. 2010
    ..Our results confirm the screening accuracy of the LFQ, a simple and effective tool to facilitate early recognition and diagnosis of COPD...
  20. ncbi The challenge of differentiating asthma from chronic obstructive pulmonary disease
    Nicola A Hanania
    Baylor College of Medicine, Houston, TX, USA
    Manag Care 14:9-15; discussion 24-6. 2005
  21. ncbi Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030, USA
    Proc Am Thorac Soc 4:526-34. 2007
    ..Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents...
  22. ncbi Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers
    Robert A Wise
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Allergy Clin Immunol 124:436-44, 444e1-8. 2009
    ..Although asthma symptoms often improve with placebo, it is not known whether the response to placebo or active treatment can be augmented by increasing expectation of benefit...
  23. ncbi Evaluation of obstructive lung disease with vibration response imaging
    Kalpalatha K Guntupalli
    Baylor College of Medicine, Ben Taub General Hospital, 1504 Taub Loop, Houston, Texas 77030, USA
    J Asthma 45:923-30. 2008
    ..Lung sound features of synchronization in timing and intensity provide objective data that may further differentiate these two airway disorders...
  24. ncbi Acute asthma in pregnancy
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Crit Care Med 33:S319-24. 2005
    ..CONCLUSIONS: Asthma can complicate the course of pregnancy, and pregnancy can worsen asthma control in some women. Optimal management of asthma during pregnancy is key in ensuring the safety of the mother and the fetus...
  25. ncbi Pathogenesis of emphysema: from the bench to the bedside
    Amir Sharafkhaneh
    Division of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Proc Am Thorac Soc 5:475-7. 2008
    ..Identification of cellular and molecular mechanisms of COPD pathogenesis is an area of active, ongoing research that may help to determine therapeutic targets for emphysema...
  26. ncbi Budesonide/formoterol combination in COPD: a US perspective
    Amir Sharafkhaneh
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Int J Chron Obstruct Pulmon Dis 5:357-66. 2010
    ..In this review, we evaluate available data of the efficacy and safety of this combination in patients with COPD...
  27. ncbi Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization
    Robert H Moore
    Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Respir Cell Mol Biol 36:254-61. 2007
    ..Defects in these components of salmeterol-induced receptor desensitization may be important determinants of its sustained bronchodilation with chronic use...
  28. ncbi Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy
    Nicola A Hanania
    Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    J Allergy Clin Immunol 113:717-24. 2004
    ..However, the effect of maintenance corticosteroid therapy on the immune response to influenza vaccine has received limited evaluation...
  29. ncbi Update on the pharmacologic therapy for chronic obstructive pulmonary disease
    Nicola A Hanania
    Asthma Clinical Research Center, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Clin Chest Med 28:589-607, vi-vii. 2007
    ..Combining a long-acting beta-agonist with an inhaled corticosteroid is more effective than either agent alone. Several novel therapies are in different stages of development...
  30. ncbi Acute asthma in pregnancy
    Elizabeth S Guy
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, 1504 Taub Loop, Houston, TX 77030, USA
    Crit Care Clin 20:731-45, x. 2004
    ..Treating physicians must overcome the common belief that pregnant women should not take any medications during pregnancy, and they should keep asthma in pregnant women under control to minimize the risk for maternal and fetal hypoxia...
  31. ncbi beta-Adrenoceptor inverse agonists in asthma
    Burton F Dickey
    Department of Pulmonary Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Opin Pharmacol 10:254-9. 2010
    ..Both lung parenchymal and hematopoietic cells appear to be involved in mediating the beneficial effects of beta-AR inverse agonists...
  32. ncbi Asthma in older adults
    Sidney S Braman
    The Warren Alpert Medical School of Brown University, Division of Pulmonary and Critical Care Medicine, and Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Clin Chest Med 28:685-702, v. 2007
    ..Adverse effects to commonly used asthma medications are more common in older adults, and careful monitoring of their use and adverse effects is important...
  33. ncbi Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Opin Pulm Med 16:1-5. 2010
    ..We review the role of beta2-AR agonist intrinsic efficacy in asthma treatment focusing on recent literature...
  34. ncbi Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease
    Francisco J Soto
    Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Curr Opin Pulm Med 11:129-34. 2005
    ..Novel anti-inflammatory therapies such as selective phosphodiesterase 4 (PDE4) inhibitors are in clinical development. Their potential role in the management of COPD is described in this review...
  35. ncbi The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA
    Pulm Pharmacol Ther 21:134-41. 2008
    ..Our findings warrant further testing in future larger trials...
  36. ncbi Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model
    Long P Nguyen
    Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Science and Research Building 2, Houston, TX 77204, USA
    Proc Natl Acad Sci U S A 106:2435-40. 2009
    ....
  37. ncbi Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population
    Amir Sharafkhaneh
    Baylor College of Medicine, Houston, TX, USA
    Int J Chron Obstruct Pulmon Dis 5:125-32. 2010
    ..Health care utilization and costs among US veterans with chronic obstructive pulmonary disease (COPD) were compared with those in veterans without COPD...
  38. ncbi Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial
    Rudolf A Baumgartner
    Sepracor Inc, Marlborough, Massachusetts 01752, USA
    Clin Ther 29:261-78. 2007
    ....
  39. ncbi The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD
    Mario Cazzola
    Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Int J Chron Obstruct Pulmon Dis 1:345-54. 2006
    ..However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone...
  40. ncbi Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials
    John P Hanrahan
    Sepracor Inc, Marlborough, MA 01752, USA
    COPD 5:25-34. 2008
    ..Arformoterol, a single isomer long-acting beta(2)-agonist, was developed as an inhalation solution for the maintenance treatment of bronchoconstriction in COPD...
  41. ncbi Predicting episodes of poor asthma control in treated patients with asthma
    Karen McCoy
    Ohio State University, USA
    J Allergy Clin Immunol 118:1226-33. 2006
    ..CLINICAL IMPLICATIONS: Simple assessments may be helpful in identifying patients most at risk for future asthma episodes...
  42. ncbi The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study
    Barry Make
    National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Clin Ther 27:531-42. 2005
    ..The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components...
  43. ncbi It's about time--directing our attention toward modifying the course of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Respir Med 102:S37-48. 2008
    ..In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy...
  44. ncbi Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study
    James F Donohue
    School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
    Clin Ther 30:989-1002. 2008
    ..Moreover, it is not clear how the different dosing regimens affect symptom outcomes and health status in hospitalized patients with asthma or COPD...
  45. ncbi A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults
    Richard Nowak
    Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA
    Am J Emerg Med 24:259-67. 2006
    ..Lev was well tolerated and compared favorably with Rac in improving airway function, particularly in those who were not on inhaled or oral corticosteroids and in those who had high plasma (S)-albuterol concentrations at presentation...
  46. ncbi Can we predict depression in COPD?
    Venkata Rebbapragada
    COPD 4:3-4. 2007
  47. ncbi One hundred years of chronic obstructive pulmonary disease (COPD)
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy
    Respir Med 101:1049-65. 2007
    ..Recent studies have documented the benefits of pulmonary rehabilitation. In addition, non-invasive mechanical ventilation offers new alternatives for patients with acute or chronic failure...
  48. ncbi Anxiety and depression in COPD: current understanding, unanswered questions, and research needs
    Janet Maurer
    Chest 134:43S-56S. 2008
    ..CONCLUSION: Future research is needed to address the impact, early detection, and management of anxiety and depression in COPD...

Research Grants2

  1. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2007
    ..abstract_text> ..